Expanded Access for ACE-011 | Reagan-Udall Foundation

Official Title

Expanded Access for ACE-011

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

Status

No longer available

EA Type

Individual Patients

Conditions

Myelodysplastic Syndrome

Interventions

Drug: ACE-011

ACE-011 will be administered subcutaneous injection
Other Name: Sotatercept

Eligibility Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

United States

Locations

Celgene
Summit, New Jersey, United States

NCT Number

NCT03724227

Keywords

Expanded Access

Compassionate Use

MeSH Terms

Myelodysplastic Syndromes

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA